Background The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is
generally poor. Recently, new classes of drugs (eg immune checkpoint inhibitors and small …

PURPOSE: To determine the short-and long-term efficacy and toxicity of the high-dose
intravenous bolus interleukin 2 (IL-2) regimen in patients with metastatic melanoma …

Background Approximately 50% of melanomas harbor activating (V600) mutations in the
serine–threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib …

Background Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as
compared with glycoprotein 100, improved overall survival in a phase 3 study involving …

The 10-year survival rate for patients with metastatic melanoma is less than 10%. Although
surgery and radiation therapy have a role in the treatment of metastatic disease, systemic …

For the past 40 years, various forms of interferon (IFN) have been evaluated as therapy in a
number of malignant and non-malignant diseases. With the advent of gene cloning, large …

Purpose Cytotoxic T lymphocyte–associated antigen 4 (CTLA4) blockade with CP-675,206,
a fully human anti-CTLA4 monoclonal antibody, may break peripheral immunologic …

This first German evidence-based guideline for cutaneous melanoma was developed under
the auspices of the German Dermatological Society (DDG) and the Dermatologic …

Purpose Chemotherapy resistance in melanoma has been linked to antiapoptotic effects
mediated by Bcl-2 protein. We evaluated whether targeting Bcl-2 using an antisense …

Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumour and
causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts …